Chronic kidney disease may result in complete kidney failure and contribute to many other health issues. Anemia is a logical consequence of the disease because the kidneys are the primary source of erythropoietin, the hormone that acts to stimulate red blood cell production in the bone marrow. All patients with chronic kidney disease are at risk for anemia, and treating anemia is extremely important to their health and well-being. Preventing or reversing the effects of anemia on the heart may decrease morbidity and mortality and improve quality of life. Many patients fail to receive treatment for anemia before requiring renal replacement therapy for end-stage renal disease. Pharmacists can play a vital role in screening, evaluating, designing proper treatment regimens, and monitoring patients with anemia of chronic kidney disease. Current recommendations regarding anemia are reviewed, including evaluation, pharmacotherapeutic agents, monitoring parameters, and goals of therapy.
Coresh J., Astor BC, Greene T., Eknoyan G., Levey ASPrevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey . Am J Kidney Dis. 2003;41:1-12.
2.
National Kidney Foundation.K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-266.
3.
McClellan W. , Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20:1501-1510.
4.
Levin A., Thompson CR, Ethier J., et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125-134.
5.
Ly J., Marticoena R., Donnelly S.Red blood survival in chronic renal failure. Am J Kidney Dis . 2004;44:715-719.
6.
Coyne D.Iron indices: what do they really mean?Kidney Int Suppl. 2006:S4-S8.
7.
Anonymous.IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update . 2000. Am J Kidney Dis. 2001 ;37 (1 suppl 1): S182-238.
8.
Ebben JP, Gilbertson DT, Foley RN, Collins AJHemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006;1:1205-1210.
9.
Collins A., Li S., St Peter W., et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36-39%. J Am Soc Nephrol. 2001;12:2465-2473.
10.
Xia H., Ebben J., Ma JZ, Collins AJHematocrit levels and hospitalization risks in hemodialysis patients . J Am Soc Nephrol. 1999;10:1309-1316.
11.
Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJAnemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis. 2002;40:1153-1161.
12.
Fink J., Blahut S., Reddy M., Light P.Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis. 2001;37:348-355.
13.
Silverberg D.Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant. 2003;18 (suppl 2):ii7-ii12.
14.
Anand ISPathogenesis of anemia in cardiorenal disease. Rev Cardiovasc Med. 2005;6 suppl 3:S13-S21.
15.
Al-Ahmad A. , Rand W., Manjunath G., et al. Reduced Kidney Function and Anemia as Risk Factors for Mortality in Patients With Left Ventricular Dysfunction . J Am Coll Cardiol. 2001;38:955-962.
16.
Ma J., Ebben J., Xia H., Collins AJHematocrit level and associated mortality in hemodialysis patients . J Am Soc Nephrol. 1999;10:610-619.
17.
United States Renal Data System. USRDS.2007Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: United States Renal Data System.
18.
Astor BC, Coresh J., Heiss G., Pettitt D., Sarnak MJKidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. [see comment]. Am Heart J. 2006;51:492-500.
19.
National Kidney Foundation.KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease. 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471-530.
20.
Brattich M.Relationships between hemoglobin and hematocrit levels and hospitalization and survival rates in dialysis patients. Nephrol Nurs J. 2003;30:231-234.
21.
Lefebvre P., Vekeman F., Sarokhan B., Enny C., Provenzano Rt, Cremieux PYRelationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin. 2006;22:1929-1937.
22.
Lim VS, DeGowin RL, Zavala D., et al. Recombinant human erythropoietin treatment in pre-dialysis patients . Ann Intern Med. 1989;110:108-114.
23.
The US Recombinant Human Erythropoietin Predialysis Study Group.Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis. 1991;18:50-59.
24.
Marrades R. , Roca J., Campistol J., et al. Effects of erythropoietin on muscle O2 transport during exercise in patients with chronic renal failure . J Clin Invest. 1997;97:2092-2100.
25.
Provenzano R., Garcia-Mayol L., Suchinda P., et al. Once-weekly epoetin alfa for treating the anemia chronic kidney disease. Clin Nephrol. 2004;61:392-405.
26.
Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25:548-554.
27.
Dean BB, Dylan M., Gano A. Jr, Knight K., Ofman JJ, Levine BSErythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease . Curr Med Res Opin. 2005;21:981-987.
28.
Kuriyama S. , Tomonari H., Yoshida H., Hashimoto T., Kawaguychi Y., Sakai O.Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;27:176-185.
29.
Jungers P., Choukroun G., Oualim Z., Robino C., Nguyen AT, Man NKBeneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant. 2001;16:307-312.
30.
Kleinman K. , Schweitzer S., Perdue S., Bleifer KH, Abels RIThe use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. Am J Kidney Dis. 1989;14:486-495.
31.
Silverberg D., Wexler D., Blum M., et al. The correction of anemia in severe resistant heart failure with erythropoietin and intravenous iron prevents the progression of both the heart and the renal failure and markedly reduces hospitalization. Clin Nephrol. 2002;58 (suppl 1):S37-S45.
32.
Levin A., Singer J., Thompson C., Ross H., Lewis M.Prevalent left ventricular hypertrophy in the pre-dialysis population: identifying opportunities for intervention. Am J Kidney Dis . 1996;27:347-354.
33.
Datta S., Abraham G., Mathew M., et al. Correlation of anemia, secondary hyperparathyroidism with left ventricular hypertrophy in chronic kidney disease patients. J Assoc Physicians India. 2006;54:699-703.
34.
Weiner DE, Tighiouart H., Vlagopoulos PT, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol. 2005;16:1803-1810.
35.
Foley R., Parfrey P., Hamett J., Kent GM, Murray DC, Barre PEThe impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53-61.
36.
Locatelli F. , Pisoni RL, Akizawa T., et al. Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings . Am J Kidney Dis. 2004;44 (5 suppl 3):27-33.
37.
Portoles J. , Torralbo A., Martin P., Rodrigo J., Herrero JA, Barrientos A.Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis. 1997;29:541-548.
38.
Hayashi T., Suzuki A., Shoji T., et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure . Am J Kidney Dis. 2000;35:250-256.
39.
Locatelli F. , Conte F., Marcelli D., The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular morbidity and mortality-the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant . 1998;13:1642-1644.
40.
Collins AJAnaemia management prior to dialysis: cardiovascular and cost-benefit observations . Nephrol Dial Transplant. 2003 ;18 (suppl 2):ii2-ii6.
41.
The National Kidney Foundation Inc Series.Who We Are. Available at www.kidney.org . Accessed: Nov 2007.
42.
National Kidney Foundation.KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47 (5 suppl 3):S11-S145.
43.
Kalantar-Zadeh K., McAllister CJ, Lehn RS, Lee GH, Nissenson AR, Kopple JDEffect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients . Am J Kidney Dis. 2003;42:761-773.
44.
Kalantar-Zadeh K., Kalantar-Zadeh K., Lee GHThe fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease?Clin J Am Soc Nephrol. 2006; 1(suppl 1): S9-S18.
45.
Fishbane S., Shapiro W., Dutka P., Valenzuela OF, Faubert J.A randomized trial of iron deficiency testing strategies in hemodialysis patients . Kidney Int. 2001;60:2406-2011.
46.
Kdoqi; National Kidney Foudnation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006. 47(5 suppl 3):S16-S85.
47.
Besarab A., Amin N., Ahsan M., et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Society of Nephrol. 2000;11:530-538.
48.
Coyne DW, Kapoian T., Suki W.Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18:975-984.
Joy MSDarbepoetin alfa: a novel erythropoiesis-stimulating protein. Ann Pharmacother. 2002;36:1183-1192.
53.
Benz R., Schmidt R., Kelly K., Wolfson M.Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin J Am Soc Nephrol . 2007:2:215-212.
54.
Provenzano R., Bhaduri S., Singh AKExtended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol. 2005;64:113-123.
55.
Provenzano R., Singh AKHemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Endocr Pract. 2007 ;13:251-259.
56.
Ling B., Walczyk M., Agarwal A., Carroll W., Liu W., Brenner R.Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol. 2005;63:327-334.
57.
Brunkhorst R., Bommer J., Braun J., Haag-Weber M., et al. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant. 2004;19:1224-1230.
58.
O'Mara N.Anemia in patients with chronic kidney disease . In: Dunsworth TS, Richardson MM, Cheng JM, et al, eds. Pharmacotherapy Self-Assessment Program , 6th ed. Kansas City, KS: American College of Clinical Pharmacy ; 2007:15-34.
59.
Scott SDDose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies.[see comment]. Pharmacotherapy . 2002;22:160S-1605S.
60.
Kruep EJ, Basskin LECost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting. Am J Health Syst Pharm. 2005;62:2597-2603.
61.
Hymes J., Bickimer T., Jackson JH, Bookhart BK, Mody SH, Tak-Piech C.Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa . Curr Med Res Opin. 2007;23:1931-1937.
62.
Icardi A., Sacco P., Salvatore F., Romano U.Long-term intravenous epoetin-alpha/darbepoetin-alpha ratio in iron-replete hemodialysis patients. J Nephrol. 2007; 20:73-79.
63.
Courtney AE , McNamee PT, Maxwell APCost should be the principal determinant of choice of erythropoiesis-stimulating agent in chronic haemodialysis patients . Nephron. 2007;107:c14-c19.
Ogden DAMonitoring considerations in recombinant human erythropoietin therapy . Semin Nephrol. 1989;9(1suppl 2):12-15.
66.
Mann JFHypertension and cardiovascular effects-long-term safety and potential long-term benefits of r-HuEPO. Nephrol Dial Transplant. 1995;10 suppl 2:80-84.
67.
Luft FCErythropoietin and arterial hypertension. Clin Nephrol . 2000;53(1 suppl):S61-S64.
68.
Novak BL, Force RW, Mumford BT, Solbrig RMErythropoietin-induced hypertensive urgency in a patient with chronic renal insufficiency: case report and review of the literature. Pharmacotherapy. 2003;23:265-269.
69.
Raine A.Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet. 1988;1:97-100.
70.
Kharagjitsingh AV, Korevaar JC, Vandenbroucke JP, et al. Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients. Kidney Int . 2005;68: 1215-1222.
71.
Boven K., Knight J., Bader F., Rossert J., Eckardt KU, Casadevall N.Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant . 2005;20 suppl 3:iii33-iii40.
72.
Collins AJ, Li S., Adamson JW, Gilbertson DTAssessment of pure red cell aplasia in US dialysis patients: the limits of the Medicare data. Am J Kidney Dis. 2004 ;43:464-470.
73.
Mandreoli M. , Finelli C., Lopez A., et al. Successful resumption of epoetin alfa after rituximab treatment in a patient with pure red cell aplasia. Am J Kidney Dis. 2004;44:757-761.
74.
Charytan C., Qunibi W., Bailie GR, Venofer Clinical Studies Group.Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron. 2005;100:c55-c62.
75.
Venofer (iron sucrose) [prescribing information]. Shirley, NY: American Regent Inc; Aug 2007 .
Bailie GR, Clark JA, Lane CE, Lane PLHypersensitivity reactions and deaths associated with intravenous iron preparations . Nephrol Dial Transplant. 2005;20:1443-9.
78.
Drueke T., Witko-Sarsat V., Massy Z., et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002;106:2212-2217.
79.
Bishu K., Agarwal R.Acute injury with intravenous iron and concerns regarding long-term safety . Clin J Am Soc Nephrol. 2006;1 suppl 1:S19-S23.
80.
Zager RAParenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease. Clin J Am Soc Nephrol . 2006;1 suppl 1:S24-S31.
81.
Guz G., Glorieux GL, De Smet R., Waterloos MA, Vanholder RC, Dhondt AWImpact of iron sucrose on leukocyte surface molecules and reactive oxygen species in haemodialysis patients. Nephrol Dial Transplant . 2006;28: 2834-2840.
82.
Sirken G., Raja R., Rizkala ARAssociation of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients. Clin Nephrol . 2006;66:348-356.
83.
Maynor L., Brophy DFRisk of infection with intravenous iron therapy. Ann Pharmacother . 2007;41:1476-1480.
84.
Teehan GS, Bahdouch D., Ruthazer R., Balakrishnan VS, Snydman DR, Jaber BLIron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis. 2004; 38:1090-1094.
85.
Brewster UC , Perazella MAIntravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial . 2004;67:57-60.
86.
Gilmartin C.Pharmacist's role in managing anemia in patients with chronic kidney disease: potential clinical and economic benefits. Am J Health Syst Pharm.2007;64 (13 suppl 8):S15-S22; quiz S3-S5.
87.
Attallah N. , Osman-Malik Y., Frinak S., Besarab A.Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. [see comment]. Am J Kidney Dis. 2006;47:644-654.
88.
Keven K., Kutlay S., Nergizoglu G., Erturk S.Combination of intravenous iron sucrose and ascorbic acid in hemodialysis patients. [comment]. Kidney Int. 2005;68:411.
89.
Tarng DC, Hung SC, Huang TPEffect of intravenous ascorbic acid medication on serum levels of soluble transferrin receptor in hemodialysis patients. J Am Soc Nephrol . 2004;15:2486-2493.
90.
Johnson DW, Pollock CA, Macdougall ICErythropoiesis-stimulating agent hyporesponsiveness. Nephrology . 2007;12:321-330.
91.
Gastaldello K., Vereerstraeten A., Nzame-Nze T., Vanherweghem JL, Tielemans C.Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant. 1995;10 suppl 6:44-47.
92.
Tarng DC, Huang TPA parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant. 1998 ;13:2867-2872.
93.
Tarng DC, Wei YH, Huang TP, Kuo BI, Yang WCIntravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int . 1999;55: 2477-2486.
94.
Lin CL, Hsu PY, Yang HY, Huang CCLow dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload. Ren Fail. 2003;25:445-453.
95.
Chan D., Irish A., Dogra G.Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients. Nephrology (Carlton). 2005; 10:336-340.
96.
Labonia WDL-Carnitine effects on anemia in hemodialyzed patients treated with erythropoietin . Am J Kidney Dis. 1995;26:757-764.
97.
Drueke TB, Locatelli F., Clyne N., et al. for the CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. [see comment]. N Engl J Med. 2006;55:2071-2084.
98.
Singh AK, Szczech L., Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease . [see comment]. N Engl J Med. 2006;55:2085-98.
99.
Milano M., Schneider M.EPO in cancer anemia: benefits and potential risks. Crit Rev Oncol Hematol. 2007;62:119-125.
100.
Hsu CY , McCulloch CE, Curhan GCEpidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002;13:504-510.
101.
Nickolas TL, Frisch GD, Opotowsky AR, Arons R., Radhakrishnan J.Awareness of kidney disease in the US population: findings from the National Health and Nutrition Examination Survey (NHANES). 1999 to 2000. Am J Kidney Dis. 2004 ;44:185-197.
102.
Bucaloiu ID , Akers G., Bermudez MC, et al. Outpatient erythropoietin administered through a protocol-driven, pharmacist-managed program may produce significant patient and economic benefits. Manag Care Interface . 2007;20:26-30.
103.
Joy MS , Candiani C., Vaillancourt BA, Chin H., Hogan SL, Falk RJReengineering clinical operations in a medical practice to optimize the management of anemia of chronic kidney disease. Pharmacotherapy. 2007; 27:734-744.
